Day: March 25, 2022

(2022-03-25) Enclosed is a pdf version of the 2021 Annual Report for Kitron ASA. The Annual Report is also available on our website, www.kitron.com. The company publishes its annual financial statements also in European Single Electronic Format (ESEF), available as an attachment to this release. This information is subject to the disclosure requirements in the Norwegian Securities Trading Act § 5-12. For further information, please contact: Cathrin Nylander, CFO, tel. +47 900 43 284E-mail: investorrelations@kitron.com About KitronKitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group is located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, China and the United States. Included the...

Scanfil plc     Stock exchange release     25 March 2022 at 8.00 a.m. EET Scanfil plc’s annual report for 2021 has been published Scanfil plc has today published its Annual Report for 2021. The Annual Report includes Sustainability Report, Report by the Board of Directors, Financial Statements, Auditor’s Report, Corporate Governance Statement, and Remuneration Report. The Financial Statements have been published under the European Single Electronic Format (ESEF) reporting requirements as XHTML file. The primary statements have been labelled with XBRL tags. The audit firm KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Scanfil’s ESEF Financial Statements. The Annual Report is attached to this release as PDF and XHTML files. Annual Report is also available at www.scanfil.com Further information: ...

First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presented Evrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy Longer-term efficacy and safety for Enspryng in neuromyelitis optica spectrum disorder reinforce previously seen results Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American Academy of Neurology...

*** Unofficial English translation – For convenience purposes only *** UCB SA/NV – Public Limited Liability CompanyAllée de la Recherche 60, 1070 BrusselsEnterprise nr. 0403.053.608 (RLE Brussels)www.ucb.com(“UCB SA/NV” or the “Company”)  CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS   The Board of Directors invites the shareholders for the ordinary and extraordinary general meeting of shareholders (the “General Meeting”) which will be held on Thursday, 28 April 2022, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 – 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Depending on the evolution of the Covid-19 pandemic and the related measures taken by our governments and public authorities, we may need to further...

GUADALAJARA, Mexico, March 25, 2022 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) informs that today was held the Investor Day 2022 (GAP DAY) at the Tijuana International Airport. The Company’s executives shared with investors, analysts, and other related parties, the short- and long-term strategies of the Company, as well as financial expectations. The GAP DAY 2022 presentation is available on the Company’s website in the Investors section. https://www.aeropuertosgap.com.mx/files/GAP_DAY_2022_VF.pdf * * * Company Description:Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos,...

COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced the pricing of its offering of US$500,000,000 aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on March 29, 2022, subject to the satisfaction of customary closing conditions. Ascendis Pharma also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes...

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of its upsized initial public offering of 4,600,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by AN2 Therapeutics. The gross proceeds to AN2 Therapeutics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AN2 Therapeutics, are expected to be $69.0 million. In addition, AN2 Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares of common stock at the initial public offering price, less...